|
|
espa�ol - fran�ais - portugu�s |
Search
|
EC Measures Concerning Meat and Meat Products (Hormones) Complaint by the United States Report of the Panel (Continued)
IV. ARGUMENTS OF THE PARTIES
1. Relationship between GATT
1994 and the SPS Agreement
IV.1 The European Communities
considered that the SPS Agreement would apply only if a violation
of the Articles of GATT were to be established. The European
Communities argued that the General Interpretative Note to Annex
1A of the WTO Agreement provided that:
IV.2 The European Communities
argued that the SPS Agreement codified, as the last recital of
its preamble stated, the desire of the Members "to elaborate
rules for the application of the provisions of GATT which relate
to the use of sanitary or phytosanitary measures, in particular
the provisions of Article XX(b)". Furthermore, it was
well established GATT law and practice that GATT 1947 did not
affect the power of its Members to set up a regulatory policy
which they deemed necessary in order to protect human, animal
or plant health. But the conformity of the measures it
applied for that purpose could be reviewed under GATT.15 It was,
therefore, admitted that a violation of GATT by a measure
should be established first, before recourse to possible justifications
(e.g. under Article XX(b)) could be considered. In such
an event, the Panel could review the measure but not the
underlying policy objective on which it was alleged to be based.
The European Communities noted that there were several new provisions
in the SPS Agreement that established a series of rights and obligations
for Members. However, the SPS Agreement reaffirmed the right
of Members to adopt or enforce measures the Member deemed to be
necessary to protect human, animal or plant health (recitals 1
and 6 of preamble). It could therefore be argued that most of
the obligations created by the SPS Agreement were already applied
under GATT 1947 through interpretations of Article XX(b)
by panel reports and the CONTRACTING PARTIES.
IV.3 The European Communities
claimed that Article 2.4 of the SPS Agreement established that
SPS measures which conformed to the Agreement were "presumed"
to be in accordance with the obligations of the Members "under
the provisions of GATT which relate to the use of sanitary or
phytosanitary measures, in particular the provisions of
Article XX(b)" (emphasis added). Despite the fact that the
words "in particular" appeared in Article 2:4, it was
hard to imagine other provisions of GATT "which relate
to the use of sanitary or phytosanitary measures".
IV.4 The European Communities
noted that, in their "Statement of Administrative Action",
the USTR had explained that:
Therefore, if the SPS Agreement
were to be defined as a self-standing agreement this was
not because it interpreted provisions of GATT other that Article
XX(b), but only because it laid down additional procedural
requirements. The substantive role of the SPS Agreement, was
to interpret Article XX(b) of GATT. In other words, recourse
to the substantive provisions of the SPS Agreement could be made
only under the same conditions under which recourse could be made
to Article XX of GATT, that was only after a violation
of another provision of GATT was first established. As far as
the additional, procedural obligations laid down by the SPS Agreement
were concerned, these could be examined by the Panel directly
and independently of any need to establish first a violation of
the provisions of GATT.
IV.5 The United States
claimed that the EC ban was subject to the SPS Agreement because
the Agreement applied to "all sanitary and phytosanitary
measures which may, directly or indirectly, affect international
trade"17 and the EC measures were sanitary measures, as defined
by the SPS Agreement, which directly and indirectly affected international
trade. The SPS Agreement was specifically tailored to SPS measures
and was the lex specialis in this instance. It made
sense to look first to the agreement most specifically designed
to address the types of measures and issues involved. The SPS
Agreement applied to all SPS measures, and applied whether
or not a Member was invoking a GATT exception for such measures.
It imposed requirements additional to those in Article III
and to the conditions for justifying the application of the exception
in Article XX(b). For instance, Article 3.2 of the SPS Agreement
provided that an SPS measure conforming to international standards,
guidelines or recommendations was presumed to be consistent with
the "relevant provisions" of not only GATT, but also
the SPS Agreement itself. The Agreement stood independently from
GATT. Thus, a complaining party did not need to first show that
an SPS measure was inconsistent with GATT before it might invoke
the provisions of the SPS Agreement.
IV.6 The United States submitted
that the negotiating record confirmed that the SPS Agreement was
intended to go beyond GATT and to impose requirements additional
to those in GATT. In the earliest phases of negotiations on SPS
issues, the discussions had focused on further definition of Article XX(b).
Up to the Dunkel Draft text (MTN.TNC/W/FA of 20 December 1991),
the SPS text was phrased as a Decision of the CONTRACTING PARTIES
interpreting the GATT, simply because participants had wished
the proposed disciplines to apply to all GATT contracting parties
and only a Decision (as opposed to an optional-membership Code)
would accomplish that result.18 However, in April 1992, when the
possibility emerged of using the MTO Agreement (later renamed
the WTO Agreement) to tie the Uruguay Round results together into
a "single undertaking", negotiators had agreed to change
the form of the text to a free-standing Agreement in Annex 1A
of the MTO Agreement.19 In contrast, the various Understandings
on GATT Articles began as decisions interpreting the GATT and
were finally incorporated into GATT. Had the negotiators intended
that the SPS Agreement be nothing but a clarification of the GATT,
in whole or in part, the United States argued, they would have
given its provisions the same form as, for instance, the Understanding
on the Interpretation of Article XVII of the GATT. The European
Communities' suggestion that the SPS Agreement could be divided
between provisions that applied to all SPS measures (and applied
under all circumstances), and other provisions which only applied
if an SPS measure violated the GATT, had no basis in the text
of the SPS Agreement.
2. The SPS Agreement
IV.7 The United States
claimed that according to the definition of sanitary and phytosanitary
measures in the SPS Agreement, whether a measure was a sanitary
measure depended on its purpose.20 The United States noted
that the purported sanitary purpose of the EC measures was stated
in the texts of the EC Council Directives themselves, and was
apparent from the history of the EC measures and subsequent statements
of the European Communities, including statements to Contracting
Parties of the GATT 1947. In reviewing the proposal for Directive
81/602/EEC, the European Economic and Social Committee had recognized
that "there is an urgent need to draw up EC provisions in
order to protect human health".21 Similarly, the debate of
the European Parliament on the proposal for Directive 88/146/EEC
underscored the claim that the EC measures were designed to protect
human health from risks associated with the use of the hormones
at issue.22 The preamble to Directive 81/602/EEC stated in
part: "Whereas, due to the residues that they leave in meat,
certain substances with a thyrostatic, oestrogenic, androgenic
or gestagenic action may be dangerous for consumers" and
"Whereas, moreover, the harmless or harmful effects of the
use of Oestradiol-17b,
Progesterone, Testosterone, Trenbolone and Zeranol still have
to be examined in detail." This concern for human health
was carried forward with Directive 88/146/EEC.23 In addition, during
the discussion in the Tokyo Round Committee on Technical Barriers
to Trade concerning the EC measures, the EC representative had
stated that the European Communities "adopted the Directive
as the best way of avoiding any health risks connected with the
use of hormonal substances".24 The United States argued
that although the European Communities had stated that the purpose
of its measures was a sanitary purpose, ostensibly to protect
human life or health within the European Communities from risks
arising from additives, contaminants, or toxins in food, the measures
were not legitimate sanitary measures.
IV.8 The European Communities
agreed with the United States that the measures challenged
were better defined as measures falling within the scope of the
SPS Agreement rather than the TBT Agreement. The European Communities
noted that an essential link of the SPS disciplines with the regulatory
freedom of the parties was that the measures applied were of concern
to the SPS Agreement (and the WTO system) only if they affected
international trade. Moreover, the SPS Agreement defined the
measures to which it applied on the basis of the objective
of the measure and the type of product to which
it was applied.
IV.9 The United States
claimed that the EC measures on their face applied to imports
of animals and meat, prohibiting imports of animals to which any
of the hormones at issue had been administered for growth promotion
purposes, and imports of meat from such animals. They clearly
affected international trade and, when they were applied, they
closed market access for significant quantities of imports from
the United States25 and other Members and continued to block imports
of animals and meat.
IV.10 The United States
observed that US exports of beef and veal to the European Communities
in the three years prior to the ban (1986-88) averaged in the
hundreds of millions of dollars, and trade to the European Communities
during the 1985-87 period was growing at about 30 per cent
per year.26 In 1989, when the ban went into effect, US exports
plummeted to nearly zero. Moreover, as a result of various rounds
of multilateral trade negotiations, the European Communities had
bound its tariffs on all products affected by the measures at
issue. In the Tokyo Round of Multilateral Trade Negotiations,
concluded in 1979 prior to the adoption of the EC measures at
issue here, the United States negotiated a quota for 10,000 tonnes
of high-quality beef subject to a tariff of 20 per cent ad
valorem and free of any variable levy. In the Uruguay Round,
this 10,000-tonne quota was converted to a tariff-rate quota and
the variable levy on beef imported in excess of 10,000 tonnes
was "tariffied". The European Communities also had
bound duties on offal products (e.g., hearts, livers, and kidneys).
As a result of the EC beef import ban, US exports of these products
to the European Communities had been substantially impaired.
IV.11 The United States
argued that the SPS Agreement was designed to ensure that no Member
maintained protectionist barriers to trade in the guise of SPS
measures and that Article 1.1 required that sanitary measures
"be developed and applied in accordance with the provisions
of this Agreement". The requirement that measures be "developed"
in accordance with the SPS Agreement did not apply here since
the EC measures were developed prior to the entry into force of
the WTO. However, the European Communities were still required
to "apply" these measures in accordance with the provisions
of the SPS Agreement.
IV.12 Moreover, in order to differentiate
between legitimate SPS measures and other types of measures, the
United States noted that the SPS Agreement provided a number of
disciplines for sanitary measures. These included an obligation
that each sanitary measure:
(ii) not be maintained without
sufficient scientific evidence;28
(iii) be based on scientific
principles;29
(iv) not be more trade-restrictive
than required to achieve the appropriate level of sanitary protection,
taking into account technical and economic feasibility;30
(v) not arbitrarily or unjustifiably
discriminate between Members where identical or similar conditions
prevailed;31
(vi) not be applied in a manner
that would constitute a disguised restriction on international
trade;32 and
(vii) be based on international
standards, guidelines or recommendations, where they existed.33
The United States claimed
that the EC measures failed each of these requirements. The EC
ban was not a legitimate sanitary measure because it severely
restricted international trade, was not applied only to the extent
necessary to protect human life or health, was not based on scientific
principles, was maintained without sufficient scientific evidence,
was not based on an assessment of the risks, and was more trade-restrictive
than required to achieve the appropriate level of protection.
It also constituted a disguised restriction on international
trade.
IV.13 The European Communities
responded that, as envisaged in the EC legislation, imports might
take place from third countries provided that guarantees were
offered that no animal and no meat coming from an animal to which
hormonal substances had been administered would be exported to
the European Communities. The EC legislation in question did
not impose a ban on US meat or on meat from any
other origin. The US exported fresh meat not destined for human
consumption and exported to the European Communities hormone-free
meat products for human consumption on the basis of measures agreed
by the joint US/EC Task Force. The US exports of meat to the
EC market for the years 1989 to 1994 were as follows: 1988:
72,557 tonnes, 1989: 8,380 tonnes, 1990: 3,617 tonnes,
1991: 1,156 tonnes, 1992: 6,320 tonnes, 1993: 6,833 tonnes,
1994: 6,594 tonnes, 1995: 8,499 tonnes.34
IV.14 The European Communities
agreed that the SPS Agreement imposed the disciplines enumerated
by the United States and considered that its measures satisfied
all those disciplines. When the EC Commission had first proposed
to the EC Council in 1980 to take measures in this area as well
as in 1988, it had found itself facing certain factual, legal
and scientific situations. From the factual point of view, consumer
concerns over the use of hormones for growth promotion in livestock
were very high. Despite the traditionally cautious approach to
the regulation of dangerous substances followed by the EC member
States, consumer confidence in science and regulators (especially
among well-informed consumer organisations and groups) was very
low. This factual situation had not changed during the entire
period that had preceded the adoption of Directive 96/22/EC.
Consumer concerns were even higher today.
IV.15 The European Communities
noted that from the legal point of view, the use of hormones in
animal growth promotion had long been prohibited in most EC member
States; only some EC member States allowed the use of some of
these substances under certain conditions.35 With the progressive
establishment of the common market, the divergence in the legislation
of EC member States was inhibiting free trade within the European
Communities in animals and meat from animals treated with some
of these hormones, and distorting the conditions of competition
among EC meat producers.
IV.16 Furthermore, the European
Communities observed that from the scientific point of view, the
situation was very unclear in the early 1980s. The relevant international
organizations - FAO, WHO, the Office internationale des épizootics
(OIE) and the Codex Commission - had started to seriously examine
the safety of these hormones in meat production only during the
1980s. The first substantive and comprehensive scientific report
had been published by OIE in 1983. JECFA had discussed and issued
a substantive and comprehensive scientific report on these hormones
only in 1988. Furthermore, none of these scientific reports
established beyond doubt that the use of these hormones in animal
growth was safe for human health. For example, in the 1983 OIE
Scientific Report it was stated:
With regard to the three so-called
"natural" hormones, the European Communities noted that
all of the above scientific reports suggested that they were "unlikely
to pose a hazard to human health" if used "in accordance
with good veterinary or animal husbandry practice".36 As regards
the other so-called "synthetic" hormones, reliable toxicological
data were still missing in the 1988 JECFA Report (page 26).
Their use for animal growth promotion had been provisionally
recommended in accordance with good animal husbandry practice
and residue checking in order to ensure that the so-called Acceptable
Residue Levels (ARLs) provisionally recommended were not
exceeded. The European Communities argued that even today the
state of scientific knowledge was not much different from what
it was in 1981 and 1988 when the challenged measures had been
adopted (as shown by the 1995 EC Scientific Conference).
IV.17 The United States
argued that although the purported major objective of the EC ban
was to protect human health, the real purpose was to protect EC
meat production from third-country competition. Noting that the
European Communities cited as the purposes of these measures (i)
protection of human health and (ii) a desire to alter the terms
of competition for animals and meat in order to render these conditions
"largely identical" within the EC market, the United States
claimed that neither reason offered a valid justification under
the WTO agreements. Furthermore, in developing the hormone ban,
the European Communities were also motivated by the fact that
the ban would help reduce surplus supplies of meat in the European
Communities and lower the cost of the EC Common Agricultural Policy.
The United States argued that this attempt to protect domestic
production from more competitive imports was protectionism and
was inconsistent with EC WTO obligations.
IV.18 The United States
noted in this regard that in April 1984, the European Communities
had introduced milk quotas to reduce the oversupply of milk, which
resulted in an increase in cattle slaughter. EC intervention
stocks of beef, which were slightly less than 400,000 tonnes in
November 1983, soared to over 800,000 tonnes by the end of 1985.
IV.19 The European Communities
rejected the US argument that the EC measures had been adopted
in order to protect domestic production from foreign competition.
The reference to the divergence in the legislation of the EC
member States which distorted the conditions of competition and
affected free circulation of products in intra-EC trade (1st and
2nd paragraphs of Directive 88/146/EEC), was made for the sole
purpose of justifying the need to take action at the EC level.
Because of its internal constitutional structure, the European
Communities was obliged to take action in order to eliminate distortions
in the conditions of competition and to increase free intra-EC
trade.37 The preamble of the Directive thus clearly explained that
the underlying objective was to respond in an harmonized way
to the effect of these hormones on human health. This objective,
however, was not in itself independent or more important than
the objective of safeguarding against risks to human and animal
health resulting from the substances at issue.
IV.20 The European Communities
further argued that action at the EC level was explicitly permitted
by Article XXIV:8(a) of GATT. It submitted that when the
European Court of Justice examined the object and purpose of Directive
85/649/EEC (invalidated on procedural grounds and subsequently
re-enacted in Directive 88/146/EEC) it had noted that "the
aim of the Directive, according to the recitals in its preamble,
is to protect human health and consumer interests with a view
to eliminating the distortion of conditions of competition and
bringing about an increase in consumption of the product in question".
IV.21 Furthermore, the European
Communities asserted that the historical record clearly demonstrated
that the purpose of the EC measures was to protect human and animal
health from risks arising from the use of the hormones at issue.
The European Communities noted that the European Parliament had
proposed a ban on imports of meat from animals treated with growth
promoting hormones primarily because "scientific information
about these substances is far from complete and that considerable
doubt therefore exists about the desirability of their use and
of their effect on human health".38 Serious health concerns
had been clearly stated in different MEP reports, including the
"Nielsen Report", the "Pimenta Report" and
the "Collins Report", and the European Parliament had
remained constantly opposed to the authorization of all these
hormones for animal growth promoting purposes for reasons of possible
hazards to human and animal health. The Economic and Social Committee
had also rejected the use of these hormones for growth promotion
purposes on health grounds. The European Communities claimed
that, from the above sequence of events which had eventually led
to the adoption of Directive 88/146/EC, it was clear that
the European Communities had examined carefully the potential
risks to human and animal health from the use of these hormones
for animal growth promotion purposes; considered that scientific
evidence, whilst suggesting that these substances, if used in
accordance with good veterinary practice, did not seem to pose
risks to human and animal health, did not exclude beyond doubt
that they posed no potential risks to human health; examined
carefully all of the available options for harmonizing the conditions
of use of these substances before concluding that, at present,
the ban on their use was the only scientifically, technically
and economically feasible option.
IV.22 The European Communities
rejected the US references to milk quotas and observed that the
increase in the EC intervention stocks of beef was unrelated to
the objective and purpose of the challenged measure. Such high
intervention stocks of beef did not exist in the EC member States
that introduced the prohibition on the use of these hormones as
early as 1961; such high intervention stocks of beef did not
exist in 1981 when this prohibition was for the first time imposed
at EC level; and such high intervention stocks of beef did not
exist in April 1996 when the European Communities adopted
Directive 96/22/EC which re-enforced the prohibition on the
use of these hormones. The European Communities further submitted
that the fact that the Directive offered equal access to the EC
market for third-country meat was additional proof that there
was no protectionist purpose in the EC measures. Statistics showed
that the European Communities had continued to import about the
same quantities of meat as before the application of the ban,
it was, however, meat from animals to which hormones for growth
promotion purposes had not been administered.
(a) Article 2.2 of the SPS
Agreement
IV.23 The United States
recalled that Article 2.2 required Members to ensure that
any sanitary measure was applied only to the extent necessary
to protect human or animal health, based on scientific principles
and not maintained without sufficient scientific evidence. The
United States argued that the European Communities had failed
to follow scientific principles, and lacked any scientific evidence
to give credence to its asserted health concerns. The European
Communities presented no evidence to contradict the long established
scientific determination that the six hormones were safe for use
as growth-promotion substances and that consumption of meat containing
the minute quantities of residues from treated animals was not
harmful to consumers.
IV.24 The United States
claimed that while the negotiators had not defined precisely "scientific
principles", at a minimum this term incorporated the scientific
method, which represented those principles and processes universally
regarded as necessary for scientific investigation, in particular
procedures for:
(ii) the systematic classification
of empirical data;
(iii) the measurement of empirical
quantities and for calculating probable errors and significant
deviations;
(iv) forming a hypothesis;
(v) analysing experimental results
using logic and mathematics; and
(vi) many other related techniques
and processes.
IV.25 The European Communities
responded that the US explanation of the concept of "scientific
principles" was a caricature of "the scientific method"
which could have been taken straight from a school textbook circa
1960. There was absolutely no reason to suppose that the Members
of the SPS Agreement had the list presented by the United States
in mind when signing it. There were many theories of science
and the "scientific method"; the European Communities
relied on biological principles when assessing the risks of using
hormones for growth promotion. Measures must be based on scientific
principles, as opposed to non-scientific ones, such as superstition.
If a measure was aimed at reducing or eliminating a risk to health,
then it must actually address that risk in a manner which could
be scientifically justified. If, for example, the measure was
aimed at eliminating a pathogenic organism from a food, there
were several methods, e.g. heating, salting, pickling, etc. which
could be scientifically proven to be effective. If, however,
a Member required prayers to be said over the food, or a ritual
dance to be performed around it, that would not be compatible
with the SPS Agreement because such methods could not be scientifically
proven to be effective.
IV.26 The European Communities
further argued that during the meetings of the Panel with scientists
on 17 and 18 February 1997, a number of experts advising
the European Communities explained their views on the potential
dangers to human and animal health from the use of these hormones
for growth promotion. None of the experts advising the Panel
argued that the experts referred to by the European Communities
did not employ scientific principles in their research. The US
Statement of Administrative Action stated that Article 2.2 of
the SPS Agreement did not require the best science nor the weight
of scientific evidence to be taken into account; it only stipulated
that there should be "scientific principles" and "sufficient"
(not absolute) scientific evidence. The European Communities
further argued that for example, Dr. Lucier had agreed with
the conclusions of the EC scientists that both the natural and
synthetic hormones were carcinogenic at low levels (the natural
hormones are carcinogenic even at existing physiological levels).
Some of the scientists who attended the meetings of the Panel
(and those of JECFA 1988) might not agree with the conclusions
of the scientists advising the European Communities or with
Dr. Lucier, but this was not relevant for the purposes of Articles 5.2,
2.2 and 3.3 of the SPS Agreement. What was important was whether,
in the scientific research employed by the EC scientists (or the
scientific reports to which they made reference in their reports),
the minimal attributes of scientific inquiry were respected.
The European Communities had not heard the opposite from
any of the scientists advising the Panel nor from the United States
and Canada. Therefore, the European Communities was allowed
to take into account their scientific views (or the views of the
scientists to which they referred in their reports) in its assessment
of the risks of these hormones for growth promotion.
IV.27 The European Communities
indicated that a logical consequence of the requirement for measures
to be based on scientific principles was that they must not be
maintained without scientific evidence. All Members
had measures in place before the SPS Agreement was drawn up, and
in the absence of this requirement it could have been argued that
the requirement for basing measures on scientific principles could
not be applied retrospectively. The SPS Agreement understandably
did not define the term "scientific evidence". It was
easier to argue that there were scientific principles, scientific
methods, scientific experiments and scientific data. But it was
difficult to define what was "scientific evidence",
since its content was relative in terms of time and was dependent
on the principles, methods, experiments and data mentioned. For
example, what might be an acceptable scientific method for one
scientist might not satisfy another, who might be more interested
in certain other scientific principles or aspects totally neglected
or only partially examined by the first scientist. For that reason
the SPS Agreement only required "sufficient", not clear
or certain, scientific evidence (Article 2.2).39 The SPS also
required Members, in their risk assessment, to taken into account
"available scientific evidence". But from the
"available" scientific evidence, a Member was entitled
to rely on that which its own scientists said was appropriate
and sufficient, and disregard other available evidence. It followed
that neither the Panel nor any other member might judge the adequacy
of the scientific evidence upon which a Member based its measure
in order to achieve its level of sanitary and phytosanitary protection.
For the same reasons, a Codex group of scientific experts could
not judge the adequacy of the scientific evidence used by a Member
of the SPS Agreement.40 In other words, if the "weight"
of available scientific evidence indicated that a substance was
not dangerous to human health, but another small or minority part
of available scientific evidence (of the same Member) argued that
there may be potential risks to human health, that Member was
entitled under the SPS Agreement to take a precautionary approach
and base its measure on the latter part of the available scientific
evidence. As the United States has said in the Statement
of Administrative Action, it is sufficient if the "government
maintaining the measures has a scientific basis for it"
(emphasis added).
IV.28 The scientific
basis of the EC Directives 81/602 and 88/146 were the following:
(ii) the 1983 OIE Scientific
Conference Report;
(iii) the 1988 JECFA Report;
(iv) the various works of relevant
international institutions, such as the International Agency for
Research on Cancer (IARC);
(v) the scientific works by
individual scientists relevant to the issue of use of hormones
in general and for animal growth in particular; and
(vi) information on the use
of these hormones for growth promotion available from other countries,
when relevant.
IV.29 For the
adoption of Directives 81/602/EEC, 88/146/EEC and 92/22/EC, apart
from the above scientific evidence, additional technical information
had been taken into account. This information consisted mainly
of the internal studies of the EC Commission, the reports of the
European Parliament, the reports of the Economic and Social Committee
and the deliberations of the Council of Ministers. For their deliberations,
the Ministers were assisted by scientific groups and individual
scientific experts, including experts from the relevant administrations
of the EC member States. For the adoption of Directive 96/22
of 29 April 1996, the 1995 EC Scientific Conference Proceedings
had also been taken into account.
IV.30 The European Communities
noted that in its first proposal to the Council on these substances,
the EC Commission had explained that controls were needed "...
in view of the effects of these substances in relation to carcinogenicity,
physiological effects and meat quality. The latter aspect is
also important as regards use of natural substances since physiological
effects may also occur when exposure to exceptional levels incidentally
takes place".41 In its second submission to the Council of
Ministers the EC Commission had explained the (zero) tolerance
levels which were being proposed and the need to take into account
the natural levels of the endogenous hormones which might occur
in animals.42 In its third expanded submission to the Council of
Ministers, the EC Commission had explained the proposed therapeutic
and zootechnical uses of the natural hormones, including the system
of control of use and marketing.43
IV.31 The European Communities
indicated that, with respect to Directive 88/146/EEC in 1982,
the Commission had created an ad-hoc Scientific Committee of
Experts on Anabolic Agents in Animal Production (chaired by Professor Lamming).
This Committee had issued an interim report on 22 September 1982
(the "Lamming Report"). The EC Scientific Veterinary
Committee gave its reaction on 9 November 1982. This
was followed by the EC Scientific Committee on Animal Nutrition
on 17 November 1982, and by the EC Scientific Committee
for Food on 4 February 1983. In essence, these Committees
supported controlled use of natural hormones, but were
opposed to the use of trenbolone and zeranol. On 12 June 1984,
the EC Commission published its proposal (COM(84)295) which envisaged
the controlled use of the three natural hormones for growth promotion
and proposed re-visiting the prohibitions on the two synthetic
hormones after completion of their scientific evaluation.
IV.32 The European Commission's
proposal was rejected by the European Parliament based on the
report of the Committee on the Environment, Public Health and
Consumer Protection and on the opinion of the Committee on Agriculture,
Fisheries and Food.44 The European Parliament, which did not approve
the proposed authorization of the three natural hormones except
for therapeutic purposes, had explained that:
"... whereas, in particular,
there seems to be doubt as to the effects on the immunity against
various diseases of animals treated with hormone cocktails and
that this in turn may lead to an increased use of antibiotics
...
"... Recognizes that there
is considerable difficulty involved in checking whether such substances
have been used because, where they have been properly administered,
the measurable residue concentrations are well within normal physiological
limits relatively soon after application;
"Believes, therefore, that
the permitted use of hormones for therapeutic purposes must be
strictly controlled and documented. ... "Rejects the authorization of artificial and natural hormones as growth promoters".
IV.33 The European Communities
concluded that, therefore, the European Parliament and the scientific
experts advising their members had carefully reviewed the scientific
evidence presented to it by the European Commission and by its
own expert committees, and had decided to reject the Commission's
proposal. The Economic and Social Committee had also reviewed
the European Commission's proposal, taking into account a very
wide range of technical and scientific expertise, and in its opinion
(29 November 1984) stressed that:
IV.34 The European Commission's
proposal was also rejected by the Council of Ministers. As a
result, the Commission amended its proposal and on 31 December
1985 the Council adopted Directive 85/649/EEC. This Directive
confirmed a ban on the use of all the substances concerned for
growth promotion purposes and established more detailed provisions
concerning authorized therapeutic use. This Directive was challenged
in the European Court of Justice, which annulled it on purely
procedural grounds. Re-introduced, the proposal was re-adopted
by the Council on 16 March 1988 (Council Directive 88/146/EEC),
prohibiting the use in livestock farming of substances having
a hormonal action.
IV.35 The European Communities
noted that in 1987, Professor Lamming had published an account
of further work undertaken by members of his group on zeranol
and trenbolone which concluded that these substances would probably
be safe when used in accordance with "accepted husbandry
practice".45 The European Communities argued that the report
had not defined this concept, and that its conclusion was based
on the unsupported assumption that their carcinogenicity was related
to their hormonal effects.
IV.36 The European
Communities indicated that subsequently, in 1988, following discoveries
of significant use of illegal growth-promoting hormonal substances
in certain EC member States, the European Parliament had established
a "Committee of Enquiry into the Problem of Quality in the
Meat Sector". This Committee had received submissions from
a wide range of scientific experts, organisations and institutions,
including meat trade and farmers' organisations, third country
producers, the pharmaceutical industry and consumers' organizations.
The outcome of the work of the Committee of Enquiry into the
Problem of Quality in the Meat Sector (the "Pimenta Report"),
was adopted by the European Parliament on 29 March 1989. The
report observed that there was no discernable health risk in the
use of the three endogenous hormones at issue where these were,
in particular, administered to castrated steers and where they
were administered in the form of slow-release implants in a part
of the animal which was not consumed (e.g. the ear) and where
a specific withdrawal period was observed before slaughter. Of
the two other hormonal substances, zeranol was regarded as being
as safe as the three endogenous hormones referred to, while with
regard to trenbolone acetate, a small residual doubt regarding
potential long-term carcinogenicity persisted. The Pimenta Report
also indicated that the Committee had been impressed with the
thoroughness and objectivity with which the scientists concerned
had produced and presented their findings. Nonetheless, the Committee
endorsed the ban on the use of hormones, noting examples where
scientific knowledge on the safety of substances had subsequently
been reversed and that "[t]he scientific evidence does not
address the question of potential interaction of these substances
with other substances or the multiplier effect of these substances
in a worst-case scenario (e.g. the administering of hormones to
an animal with an already high level of endogenous hormones and
the ingestion of the meat (or milk) of that animal by a female
taking the oestrogen-based contraceptive pill" (page 6).
IV.37 The European Communities
noted that the Pimenta Report had concluded that successful regulations
could not be based solely on scientific information, partly because
of the "current state of knowledge" argument, and partly
because the regulatory process had to resolve social and political
conflicts that extended beyond scientific considerations. Although
the decision-making process in controversial socio-economic and
environmental issues had to take into account the scientific evidence,
it was essential that the final decision rest with society itself
through its elected representatives. The report noted that what
might appear to be a public rejection of science was more plausibly
related to a question of confidence in the adequacy of regulatory
control. The Committee was unconvinced that the legalization
of the five natural/nature-identical hormones for growth-promotion
would prevent the use of harmful black-market alternatives. It
observed that producers were still using easily-detectable synthetic
substances because of the continued attractiveness of these products
and the economic gain to be obtained from their use. These were
also incentives not to follow the conditions for administration
specified by the Lamming Committee.
IV.38 In this respect, the Pimenta
Report noted that "upstream" controls were essential,
beginning with testing blood and urine samples of live animals
on the farm. The processes of metabolism, dilution and excretion
in the living animal meant that the longer the interval between
administration of the substance and testing of the live animal
or carcass, the more difficult it was to detect the metabolites
characteristic of the use of illicit substances. In addition,
once the carcass was slaughtered and butchered, detection of metabolites
and tracing back to the animal became very difficult. However,
testing for synthetic substances posed no significant problems,
although the degree of capability and sophistication of detection
varied enormously between EC member States. In addition, methods
of chemical masking and other sophisticated techniques were being
increasingly used. While testing for the three natural hormones
posed a problem in that the range of levels of these hormones
produced naturally in the body of the animal was so large and
variable, ranges of levels could be drawn up, taking into account
the sex, age, oestral cycle and condition of the animal. If tests
showed that an animal, for no apparent reason, was at or above
the upper limit, then testing on other animals in the herd could
provide valid evidence since the statistical possibility of an
entire herd possessing above-average hormone levels was minute.
IV.39 The Committee
reported that ten out of twelve veterinary authorities from the
EC member States agreed that a total ban on administered hormones
would be easier to police than a partial ban, because veterinarians
could generally tell by visual signs when an animal had been treated
with hormones (the shape of the animal and the sexual organs were
altered) but not whether this had been a treatment with legal
versus illegal substances. Furthermore, psychologically, a total
ban was more effective than a partial one in that regulators,
producers and consumers were left in no doubt that the administration
of any hormonal substance for growth promotion purposes was not
allowed. The control of the whole meat production chain in Europe
would have to be equally rigorous whether all hormonal substances
or only some hormonal substances were banned for growth promotion
purposes. Inspection would need to be just as comprehensive and
rigorous. The Pimenta Report concluded that severe sanctions
would have to be imposed on those flouting the ban to overcome
the strong economic incentives to use growth promotion substances,
and that this problem had to be tackled in order for a ban to
be effective and for confidence to be restored in the meat sector
(page 13).
IV.40 The European Communities
added that the European Parliament had adopted another important
report on the issue of use of hormones for animal growth promotion,
the "Collins Report" of 7 February 1989.46
This report proposed that the EC veterinary medicine licensing
system be adapted to include a "fourth hurdle", entailing
an objective socio-economic and environmental impact assessment
in addition to safety, quality and efficacy criteria. It argued
that the social, agricultural and environmental implications of
the use of growth and yield promoting pharmaceuticals required
a licensing system different from that which existed for these
products when used for therapeutic purposes.
IV.41 The European Communities
indicated that the European Commission, in close cooperation with
EC member States, had continued to review the application of Directive
88/162 in the appropriate scientific and management committees.
After the entry into force of the SPS Agreement, the European
Communities had decided to review once again the situation from
the scientific point of view. For that reason, it had organized
the 1995 EC Scientific Conference in Brussels. In light of the
findings of that conference and other evidence, the European Commission
had proposed to the Council of Ministers to maintain the prohibition
on the use of these hormones for growth promotion, to further
restrict their use for therapeutic or zootechnical purposes, to
reinforce the provisions on control and testing, and to increase
substantially the penalties and sanctions in case of violations.47
Both the European Parliament48 and the Economic and Social Committee49
approved the Commission's proposal. The Council of Ministers
adopted the new Directive 96/22 of 29 April 1996, which will replace
Directive 88/146/EEC and the other relevant Directives as from
1 July 1997. IV.42 The United States argued that the European Communities had failed to comply with Article 2.2 which prohibited a Member from maintaining sanitary and phytosanitary measures "without sufficient scientific evidence". The proposal for a Council Directive submitted by the EC Commission on 13 June 1984 explicitly admitted that "on scientific grounds, it appears that the use of oestradiol-17ß, testosterone and progesterone, and those derivatives which readily yield the parent compound on hydrolysis after absorption from the site of application, would not present any harmful effects to the health of the consumer nor harm the consumer by altering the characteristics of meat when used under the appropriate conditions as growth promoters in farm animals".50 The United States added that there was absolutely no new scientific evidence considered by the Commission prior to the change in the proposed Directive to ban the use of these hormones. Indeed, in response to the 1995 EC Scientific Conference Proceedings, EC Agriculture and Rural Affairs Commissioner Fischler had confirmed that these hormones did not pose a danger to health when used in beef production. However, rather than deciding to modify the ban to reflect the scientific evidence, Mr. Fischler had indicated that this was a political matter and had noted that a 10 million ECU advertising campaign extolling the virtues of eating hormone-free meat had been launched and that the EC Council would be pressed to introduce tougher monitoring measures. The United States concluded that, in the absence of any identifiable risk from these hormones and without any supporting scientific evidence for the ban, the EC measures were not "applied only to the extent necessary to protect human, animal or plant life or health" and were not "based on scientific principles", contrary to Article 2.2. Indeed, the EC approach was contrary to scientific principles. TO CONTINUE WITH EC MEASURES ON MEAT - COMPLAINT BY THE U.S. 15 See, e.g. the panel report on "Thailand - Restrictions on Importation of and Internal Taxes on Cigarettes", adopted on 5 October 1990, DS10/R. 16 US Statement of Administrative Action, p.87. 17 Article 1.1 of the SPS Agreement. 18 "Given the desire of participants for the application of the proposed disciplines to all contracting parties, this draft has been presented in the form of a Decision of the CONTRACTING PARTIES on the Application of Sanitary and Phytosanitary Measures. However, this is without prejudice to the final form the agreement might take." MTN.GNG/NG5/WGSP/7, 20 November 1990, p.1. 19 P.21 of document 707 dated 15 April 1992, "Review of Individual Texts in the Draft Final Act (Texts on Agriculture), Informal Note by the Secretariat" (Secretariat proposal to rectify the form to change it from a decision to an agreement), and p.19 of document 963 dated 10 June 1992, "Review of Individual Texts in the Draft Final Act, Informal Note by the Secretariat" (record of rectifications agreed in the Legal Drafting Group in April 1992, including this change in form). The paragraphing of the text was rearranged into article format during the legal drafting process for the Marrakesh Final Act in February 1994. Secretariat proposals for rectifications at p.71 of MTN/FA/Corr.2 dated 18 February 1994, and agreed rectifications in MTN/FA/Corr.5 dated 11 March 1994. 20 Article 2.1 of the SPS Agreement. The United States argued that the European Communities was mistaken in its perception of the coverage of the SPS Agreement. The EC claim that sanitary and phytosanitary measures were defined based in part on the type of product to which the measure applied was incorrect. Nothing in the SPS Agreement limited its coverage by the type of product. The SPS Agreement applied to any sanitary or phytosanitary measure. For example, measures restricting the importation of construction equipment to ensure that it was not carrying soil with plant pests or diseases, or that it did not harbour plant pests, were phytosanitary measures, even though they applied to construction equipment. The same would be true for measures applicable to lawn furniture to ensure that it did not harbour cocoons of a plant pest, or measures applicable to tires to make sure they did not host mosquitoes carrying infectious diseases for humans. 21 Paragraph 1.2 of the opinion, EC Official Journal No C 138/29, 9 June 1981. This opinion is cited in the preamble to Directive 81/602/EEC. 22 Debate published in the Annex to the EC Official Journal No 2-330 of 10 October 1985, beginning, p.232. 23 Directive 88/146/EEC states that: "Whereas the administration to farm animals of certain substances having a hormonal action is at present regulated in different ways in the member States; whereas while their immediate effect on animals from the farmer's point of view is clear, assessments of their effect on human health vary and this is reflected in the regulations governing their use; whereas this divergence distorts the conditions of competition in products that are the subject of common market organizations and is a serious barrier to intra-EC trade." 24 Paragraph 12, TBT/M/Spec/7 (Committee on Technical Barriers to Trade, Minutes of Meeting held on 23 July and 28 July 1987). See also paragraph 6 of TBT/M/Spec/7 ("The complaint of the United States should not deter his authorities from applying the measures that they had adopted to protect the health and safety of their population."), as well as paragraphs 9 and 24. See also paragraphs 11 through 13 of TBT/M/Spec/5. 25 According to a table provided by the United States, an average 70 per cent of all US cattle were treated with one or more of these hormones. 26 The United States estimated in 1988 that the EC measures cut off approximately $100 million in US exports. 27 Article 5.1 of the SPS Agreement. 28 Ibid., Article 2.2. 29 Ibid., Article 2.2. 30 Ibid., Article 5.6. 31 Ibid., Article 2.3. 32 Ibid., Article 2.3. 33 Ibid., Article 3.1. 34 The European Communities explained that the figures were based on Eurostat statistics. 35 The European Communities indicated that 4 or 5 EC member States allowed the use of some of these hormones for growth promotion until their prohibition at EC level. The information on level of use, if available at all, would only be known to those individual EC member States. One EC member State, the United Kingdom, had indicated that anecdotal evidence suggested that growth promoting hormones might have been used up to 40 per cent of the United Kingdom cattle prior to the ban. 36 1988 JECFA Report, pp.19 et seq. 37 The European Communities noted that this obligation resulted from Articles 100 and 100A, in conjunction, in this case, with Articles 30 and 36 of the EC Treaty. 38 Point E of Parliament's Resolution, EC Official Journal No 288, 11 November 1985, p.158. 39 On the other hand, the European Communities noted that the term "scientific evidence" had a different meaning from the requirement to provide "evidence" in a legal trial. 40 See, for example, the article by D.A. Wirth (1994), "The role of Science in the Uruguay Round and the NAFTA Trade Disciplines", 27 Cornell International Law Journal, 817-859, at 856-57. 41 COM(80)614 of 31 October 1980. 42 COM(80)920 of 6 January 1981. 43 COM(80)922 of 6 January 1981. 44 European Parliament Doc. A2-100/85 of 11 October 1985. 45 The Veterinary Record, 24 October 1987, p.389. 46 European Parliament, Committee on the Environment, Public Health and Consumer Protection, Report on "The USA's Refusal to comply with EC Legislation on Slaughterhouses and Hormones and the Consequences of this Refusal", EP 128 381/B, 7 February 1989, named after its reporter Mr. Collins, MEP. See para. 2.32. 47 EC Official Journal C 302, 9 November 1993, p.8 and C 222, 10.8.1994, p.16. 48 EC Official Journal C 128, 9 May 1994, p.105. 49 EC Official Journal C 52, 19 February 1994, p.30. 50 COM(84)295 final, clause 13 of the preamble, 29 June 1984, Official Journal C 170, p.4 seq. |
|